CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
February 11th 2025
Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.
Elie Fahed, MD, provides an overview of what multiple myeloma is, and Beth walks us through her frustrating journey to initial diagnosis as an atypical patient.
FDA Approves First CAR-T Cell Therapy for Multiple Myeloma
March 28th 2021Abecma is the first cell-based gene therapy approved for the treatment of patients with relapsed and refractory multiple myeloma who did not respond to at least four treatments, or whose disease returned after those four lines of therapy.
Multiple Myeloma 101: An Incurable But ‘Very Treatable’ Disease
March 22nd 2021Although a multiple myeloma diagnosis can be overwhelming for patients, an expert from the Massachusetts General Hospital Cancer Center notes how the disease is very treatable, and that patients can go on to lead full lives.
Novel Drug with Dexamethasone Safe in Heavily Pretreated Multiple Myeloma
January 13th 2021Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.
Clinical Trials on Smoldering Myeloma May Open Doors to More Precision Medicine
December 29th 2020In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.
FDA Approves Xpovio for Use with Velcade and Dexamethasone in Multiple Myeloma
December 18th 2020This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.
Understanding New Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
December 15th 2020The complexity of multiple myeloma can make it difficult to treat, but with complexity comes more avenues for researchers to explore what treatments work best. Recently, CURE® spoke with an expert from Dana-Farber Cancer Institute on what patients can expect to see from the clinical setting.
Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma
December 4th 2020Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.
Adding Darzalex to Standard Treatment for High-Risk Multiple Myeloma May Delay Disease Progression
October 27th 2020A meta-analysis of six clinical trials showed that standard treatment regimens for high-risk multiple myeloma may be more effective at delaying disease progression if they are given in combination with the targeted drug Darzalex (daratumumab).
Velcade-Based Triplet Regimen ‘Should Remain’ Standard of Care in Newly Diagnosed Multiple Myeloma
September 10th 2020When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.